IceCure Medical Ltd. (NASDAQ:ICCM) Receives Average Rating of “Moderate Buy” from Brokerages

IceCure Medical Ltd. (NASDAQ:ICCM) has been given an average rating of “Moderate Buy” by the five brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $2.6350.

ICCM has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IceCure Medical in a research note on Saturday, September 27th. Loop Capital set a $2.77 price objective on IceCure Medical in a research report on Wednesday, August 13th. Zacks Research lowered IceCure Medical from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 15th. Wall Street Zen cut IceCure Medical from a “hold” rating to a “sell” rating in a report on Saturday, July 12th. Finally, Brookline Capital Management restated a “buy” rating on shares of IceCure Medical in a report on Wednesday, August 13th.

IceCure Medical Stock Performance

NASDAQ:ICCM opened at $1.00 on Friday. The company has a current ratio of 1.18, a quick ratio of 0.88 and a debt-to-equity ratio of 0.02. IceCure Medical has a 12-month low of $0.48 and a 12-month high of $1.66. The stock has a 50-day moving average price of $0.98 and a 200 day moving average price of $1.04. The stock has a market capitalization of $68.69 million, a P/E ratio of -6.25 and a beta of 0.31.

IceCure Medical (NASDAQ:ICCM) last announced its quarterly earnings data on Wednesday, August 13th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.12. IceCure Medical had a negative net margin of 317.62% and a negative return on equity of 136.96%. The business had revenue of $0.66 million during the quarter, compared to analyst estimates of $0.90 million. Equities research analysts forecast that IceCure Medical will post -0.28 EPS for the current fiscal year.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.